UNASSIGNED: The role of allogeneic @entity8 ( @entity8 ) in the management of @entity146 @entity1893 ( @entity1893 ) remains to be defined, but the number of procedures performed continues to increase. We report here the outcomes of allogeneic @entity8 using @entity3600 , @entity2879 , @entity2592 , and @entity3601 (BEAM)-Campath (Genzyme Corporation, Cambridge, MA) conditioning for @entity1893 as reported to the British Society of Blood and Marrow Transplantation (BSBMT). This retrospective study identified 46 @entity1 who reported to the BSBMT registry as having undergone BEAM-Campath conditioned allogeneic @entity8 for @entity1893 between 1999 and 2010. Disease histology was @entity1892 ( @entity1892 , n  =  25), @entity1892 / @entity2109 (n  =  5), and @entity784 (n  =  16). At diagnosis, the median age was 42.5 (range, 17 to 59), 37 had advanced stage disease (Ann Arbor III/IV), 28 had 2 or more extra-nodal sites of disease, and 23 had elevated @entity880 dehydrogenase. International prognostic index was high or high/intermediate in 58%. The median number of prior therapies was 3 (range, 1 to 5) and 5 @entity1 had previously undergone transplantation (4 autologous, 1 allogeneic). The median age at transplantation was 44.8 (range, 18 to 59), with 34 @entity1 demonstrating @entity66 and 22 undergoing transplantation in first response. Performance score was good in 40 @entity1 and all engrafted with a median of 14  days (range, 11 to 27) to neutrophil recovery. At latest follow-up, 20 @entity1 were alive with 17 in complete remission. @entity2132 ( @entity2132 ) developed in 7 @entity1 and chronic @entity2132 developed in 13 (7 limited, 6 extensive). Five @entity1 died from nonrelapse causes, with a cumulative incidence of nonrelapse mortality of 7% at 100  days and 11% at 3 and 5  years. Twenty-one @entity1 died after lymphoma relapse, with a cumulative incidence of relapse/progression of 51% at 1  year and 53% at 5  years. Disease status at transplantation had no impact on relapse rate. Progression-free survival was 41% at 1  year and 36% at 5  years. Overall survival was 54% at 1  year and 42% at 5  years. Overall, BEAM-Campath-conditioned allogeneic @entity8 is well tolerated and able to deliver durable disease-free survival to a subset of @entity1 with @entity1893 . However, the high relapse rates indicate further investigation is needed to identify those @entity1 most likely to benefit.

@entity3600 , @entity2879 , @entity2592 , and Melphalan (BEAM)-Campath Allogeneic Stem Cell Transplantation for Aggressive XXXX : An Analysis of Outcomes from the British Society of Blood and Marrow Transplantation.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity8 :: ('MESH:D007674', 'Disease') :: ['SCT', 'stem cell transplantation'] @entity66 :: ('MESH:D004194', 'Disease') :: ['chemo-sensitive disease'] @entity146 :: ('MESH:D001523', 'Disease') :: ['aggressive'] @entity784 :: ('MESH:D016399', 'Disease') :: ['T cell lymphoma'] @entity2109 :: ('MESH:D002051', 'Disease') :: ['Burkitt lymphoma'] @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide'] @entity2592 :: ('MESH:D003561', 'Chemical') :: ['cytarabine'] @entity3600 :: ('MESH:D002330', 'Chemical') :: ['carmustine'] @entity3601 :: ('MESH:D008558', 'Chemical') :: ['melphalan'] @entity1892 :: ('MESH:D016393', 'Disease') :: ['DLBCL', 'diffuse large B cell lymphoma'] @entity2132 :: ('MESH:D006086', 'Disease') :: ['GVHD', 'Acute graft-versus-host disease'] @entity880 :: ('MESH:D019344', 'Chemical') :: ['lactate'] @entity1893 :: ('MESH:D008228', 'Disease') :: ['NHL', 'non-Hodgkin lymphoma', 'aggressive NHL']
@entity1893 :: (MESH:D008228,Disease) :: ['Non-Hodgkin Lymphoma']
